Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-10-30
2007-10-30
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S387900, C530S388800, C530S388850
Reexamination Certificate
active
10247488
ABSTRACT:
More than 90% of mutations found in the p53 protein produce a conformational change in p53 which results in the exposure of an epitope, which is otherwise hidden in the hydrophobic core of the molecule. A single chain antibody (scFv) which specifically recognizes this common mutant epitope in mutant p53 but not in wild type p53 is disclosed. Also described are a DNA molecule encoding the scFv, pharmaceutical compositions comprising the antibody and methods of treatment using the pharmaceutical compositions.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5756669 (1998-05-01), Bischoff et al.
patent: 6630584 (2003-10-01), Solomon et al.
patent: 2002/0155114 (2002-10-01), Marks et al.
Rudikoff et al (Proc. Natl. Acad. Sci. USA 1982 vol. 79 p. 1979).
Burgess et al, Journal of Cell Biology vol. 111 Nov. 1990 2129-2138.
Lazar et al Molecular and Cellular Biology Mar. 1988 vol. 8 No. 3 1247-1252.
Schwartz et al, Proc Natl Acad Sci USA vol. 84:6408-6411 (1987).
Lin et al Biochemistry USA vol. 14:1559-1563 (1975).
Acland et al., Nature vol. 343:662-665 (1990).
Ibragimova and Eade (Biophysical Journal, Oct. 1999, vol. 77, pp. 2191-2198).
Orlandi et al (Proc. Natl. Acad. Sci. USA, 86:3833-3837, 1989).
Marasco, W.A., “Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy”,Immunotechnology, vol. 1, pp. 1-19, (1995).
Jannot, C.B., et al., “Characterization of scFv-421, a Single-Chain Antibody Targeted to p53”,Biochemical and Biophysical Research Comm., vol. 230, No. 2, pp. 242-246, (1997).
Yewdell, J.W., et al., “Monoclonal Antibody Analysis of p53 Expression in Normal and Transformed Cells”,Journal of Virology, vol. 59, No. 2, pp. 444-452, (Aug. 1986).
Harlow, E., et al., “Monoclonal Antibodies Specific for Simian Virus 40 Tumor Antigens”,Journal of Virology, Vo. 39, No. 3, pp. 861-869, (Sep. 1981).
Gannon, J.V., et al., “Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form”,The EMBO Journal, vol. 9, No. 5, pp. 1595-1602, (1990).
Gamble, J., et al., “Evidence that Immunological Variants of p53 Represent Alternative Protein Conformations”,Virology, vol. 162, pp. 452-458, (1988).
Stephen, C.W., et al., “Mutant Conformation of p53 Precise Epitope Mapping Using a Filamentous Phage Epitope Library”,J. Mol. Biol. vol. 225, pp. 577-583, (1992).
Cohen, P.A., et al., “Characterization of a new intrabody directed against the N-terminal region of human p53”,Oncogene, vol. 17, pp. 2445-2456, (1998).
Milner, J., et al., “A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40”,Oncogene, vol. 1, pp. 453-455, (1987).
Bowie et al., Science, vol. 247, pp. 1306-1310, 1990.
Burgess et al., Journal of Cell Biology, vol. 111, pp. 2129-2138, 1990.
Lazar et al., Molecular and Cell Biology, vol. 8, pp. 1247-1252, 1988.
Bork, Genome Research, vol. 10, pp. 398-400, 2000.
Jones et al., Advanced Drug Delivery Reviews, vol. 31, pp. 153-170, 1998.
Anderson, Nature, vol. 392, pp. 25-30, 1998.
Verma et al., Nature, vol. 389, pp. 239-242, 1997.
Ross et al., Human Gene Therapy, vol. 7, pp. 1781-1790, 1996.
Cohen et al., Science, vol. 265, pp. 1371-1371, 1994.
Cohen et al. “Characterization of A New Intrabody Directed Against the N-Terminal Region of Human P53”, Oncogene, 17(19): 2445-2456, 1998. Abstract, p. 2452, col. 1; Claims: 1-29.
Caron de Fromentel et al. “Restoration of Transcriptional Activity of P53 Mutants in Human Tumour Cells by Intracellular Expression of Anti-P53 Single Chain Fv Fragments”, Oncogene, 18(2): 551-557, 1999. Abstract, p. 556, Fig.6; Claims: 1-29.
Jannot et al. “Characterization of SCFV-421, A Single-Chain Antibody Targeted to P53”, Biochemical and Biophysical Research Communications, 230(2): 242-246, 1997. Abstract, p. 245, col. 1-2; Claims: 1-29.
Govorko et al. “Single-Chain Antibody Against the Common Epitope of Mutant P53: Isolation and Intracytosolic Expression in Mammalian Cells”, Journal of Immunological Methods, 258(1-2): 169-181, 2001. Abstract. p. 179, col. 2; Claims: 1-29.
Fischer-Fantuzzi et al. “Cell-Dependent Efficiency of Reiterated Nuclear Signals in A Mutant Simian Virus 40 Oncoprotein Targeted to the Nucleus”, Mol. Cell Biol., 8(12): 5495-5503, 1988. Abstract.
Pavlinkova et al. “Effects of Humanization and Gene Shuffling on Immunogenicity and Antigen Binding of Anti-TAG-72 Single-Chain Fvs”, Int. J. Cancer, 94(5): 717-726, 2001. Abstract.
Cheson “Rituximab: Clinical Development and Future Directions”, Expert. Opin. Biol. Ther., 2(1): 97-110, 2002. Abstract.
Grillo-Lopez et al. “Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkin's Lymphoma”, Curr. Pharm. Biotechnol., 2(4): 301-311, 2001. Abstract.
Kashmiri et al. “Development of A Minimally Immunogenic Variant of Humanized Anti-Carcinoma Monoclonal Antibody CC49”, Crit. Rev. Oncol. Hematol., 38(1): 3-16, 2001. Abstract.
Keating et al. “Emerging Information on the Use of Rituximab in Chronic Lymphocytic Leukemia”, Semin. Oncol., 29(1 Suppl.2): 70-74, 2002. Abstract.
Hortobagyi “Overview of Treatment Results With Trastuzumab (Herceptin) in Metastatic Breast Cancer”, Semin. Oncol., 28(6 Suppl.18): 43-47, 2001. Abstract).
Munro et al. “A C-Terminal Signal Prevents Sectetion of Luminal ER Proteins”, Cell, 48(5): 899-907, 1987. Abstract.
Silver “How Proteins Enter the Nucleus”, Cell, 64(3): 489-497, 1991. Abstract.
Wu et al. “Humanization of A Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues”, J. Mol. Biol., 294(1): 151-162, 1999. Abstract.
Barbas et al. “Selection and Evolution of High-Affinity Human Anti-Viral Antibodies”, TIBTECH, 14: 230-234, 1996.
Brown et al. “Tolerance to Single, But Not Multiple, Amino Acid Replacements in Antibody VH CDR2. A Means of Minimizing B Cells Wastage From Somatic Hypermutation?”, The Journal of Immunology, 156: 3285-3291, 1996. Abstract.
Nishimiya et al. “Thermodynamic Consequences of Grafting Enhanced Affinity Toward the Mutated Antigen Onto An Antibody. The Case of Anti-Lysozyme Antibody, HyHEL-10”, The Journal of Biological Chemistry, 275(17): 12813-12820, 2000.
Gamble et al. “Evidence That Immunological Variants of P53 Represent Alternative Protein Conformations”, Virology, 162(2): 452-458, 1988. Abstract.
Gannon et al. “Activating Mutations in P53 Produce A Common Conformational Effect. A Monoclonal Antibody Specific for the Mutant Form”, The EMBO Journal, 9(5): 1595-1602, 1990.
Harlow et al. “Monoclonal Antibodies Specific for Simian Virus 40 Tumor Antigens”, Journal of Virology, 39(3): 861-869, 1981.
Marasco “Intracellular Antibodies (Intrabodies) as Research Reagents and Therapeutic Moleculaes for Gene Therapy”, Immunotherapy, 1: 1-19, 1995.
Milner et al. “A New Anti-P53 Monoclonal Antibody, Previously Reported to Be Directed Against the Large T Antigen of Simian Virus 40”, Oncogene, 1(4): 453-455, 1987.
Murray et al. “Codon Usage in Plant Genes”, Nucleic Acids Research, 17(2): 477-498, 1989.
Smythe et al. “Production of Linear Polymers of HIV Gp120-Binding Domains”, Protein Engineering, 7(2): 145-147, 1994. Abstract.
Stephen et al. “Mutant Confimation of P53 *1. Precise Epitope Mapping Using A Filamentous Phage Epitope Library”, Journal of Molecular Biology, 225(3): 577-583, 1992. Abstract.
Yewdell et al. “Monoclonal Antibody Analysis of P53 Expression in Normal and Transformed Cells”, Journal of Virology, 59(2): 444-452, 1986.
Verma et
Cohen Gerald
Govorko Dimitri
Solomon Beka
Blanchard David J.
Ramot At Tel Aviv University Ltd.
Tungaturthi Parithosh K.
LandOfFree
Single chain antibody against mutant p53 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Single chain antibody against mutant p53, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Single chain antibody against mutant p53 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3826650